Logiscreen

ReShape Lifesciences Inc

$2.18
Market Cap 15.30M
ROE -251.9%
Gross Margin 52.7%
Debt/Equity 0.0
Current Ratio 4.3
Revenue QoQ -84.1%
EPS QoQ -1.0%
F-Score 4

About

ReShape Lifesciences ® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band ® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon ® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Devices

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-1.27
vs median 35.63
P/B
2.01
vs median 2.25
ROE
-2.52
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics